MyoKardia Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
Highlights
MyoKardia Inc (MyoKardia) is a clinical stage biopharmaceutical company. The company utilizes precision medicine platform to develop therapies for the treatment of serious and rare cardiovascular diseases including heritable cardiomyopathies. Its lead drug product candidate, mavacamten, is intended for the treatment of hypertrophic cardiomyopathy (HCM). Its other pipeline product candidates include danicamtiv (formerly MYK-491) is being developed for treating genetic dilated cardiomyopathy (DCM) and systolic heart failure; MYK-224, a small molecule for treating HCM; ACT-1 for systolic heart failure, and LUS-1, for treating diastolic heart failure. The company collaborates with healthcare organizations for the development and commercialization of its pipeline products. MyoKardia is headquartered in Brisbane, California, the US.
MyoKardia Inc Key Recent Developments
Nov 25,2020: MyoKardia reports third quarter 2020 financial results
Nov 18,2020: BMS acquires biopharma firm MyoKardia for $13.1bn
Nov 11,2020: MyoKardia collaborates with the American College of Cardiology and PINNACLE/veradigm to launch patient registry of hypertrophic cardiomyopathy
Nov 04,2020: MyoKardia announces awardees of the second annual MyoSeeds Research Grants Program
Oct 06,2020: BMS to acquire biopharma firm MyoKardia for $13.1bn
Reasons to Buy
Note: Some sections may be missing if data is unavailable for the company.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - The Publisher’s summarization of the company’s business strategy.
- SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.
Highlights
MyoKardia Inc (MyoKardia) is a clinical stage biopharmaceutical company. The company utilizes precision medicine platform to develop therapies for the treatment of serious and rare cardiovascular diseases including heritable cardiomyopathies. Its lead drug product candidate, mavacamten, is intended for the treatment of hypertrophic cardiomyopathy (HCM). Its other pipeline product candidates include danicamtiv (formerly MYK-491) is being developed for treating genetic dilated cardiomyopathy (DCM) and systolic heart failure; MYK-224, a small molecule for treating HCM; ACT-1 for systolic heart failure, and LUS-1, for treating diastolic heart failure. The company collaborates with healthcare organizations for the development and commercialization of its pipeline products. MyoKardia is headquartered in Brisbane, California, the US.
MyoKardia Inc Key Recent Developments
Nov 25,2020: MyoKardia reports third quarter 2020 financial results
Nov 18,2020: BMS acquires biopharma firm MyoKardia for $13.1bn
Nov 11,2020: MyoKardia collaborates with the American College of Cardiology and PINNACLE/veradigm to launch patient registry of hypertrophic cardiomyopathy
Nov 04,2020: MyoKardia announces awardees of the second annual MyoSeeds Research Grants Program
Oct 06,2020: BMS to acquire biopharma firm MyoKardia for $13.1bn
Reasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with the publisher’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
Table of Contents
List of Figures
Section 1 - About the Company
Section 2 – Company Analysis
Section 3 – Company’s Lifesciences Financial Deals and Alliances
Section 4 – Company’s Recent Developments
Section 5 – Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen Inc
- Zensun (Shanghai) Sci & Tech Co Ltd
- Novartis Corp
- Takeda Pharmaceuticals America Inc
- Bayer AG